IZEA:NASDAQIZEA Worldwide, Inc. Analysis
Data as of 2026-07-13 - not real-time
$3.58
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
IZEA is trading at $3.58, just under its 20‑day simple moving average of $3.59, and well below both the 50‑day ($3.79) and 200‑day ($4.15) averages, signaling a bearish price structure. The 14‑day RSI sits at 46.5, indicating neutral momentum but edging away from oversold territory. MACD shows a modest bullish crossover with the line above the signal and a positive histogram of 0.014, yet the magnitude is tiny. Volume has been on a downward trajectory, and the 30‑day volatility is a lofty 38.9%, reflecting an erratic trading pattern. The computed beta of 0.44 suggests the stock moves less than the broader market, but the high realized volatility offsets that benefit. Support at $3.34 and resistance near $3.78 frame a narrow trading range that the price has struggled to break upward.
On the fundamentals side, revenue has contracted 17.5% year‑over‑year to roughly $29.8 million, and margins are deep in the red (gross margin 48%, operating margin –17.8%). The company posted a trailing EPS of –$0.03 and a forward EPS of –$0.41, resulting in a negative forward P/E of –8.73, which renders traditional valuation ratios less informative. Nevertheless, the balance sheet is strong, with $46.5 million in cash and virtually no debt (debt‑to‑equity 0.5%). The price‑to‑book of 1.28 and price‑to‑sales of 2.10 are modest compared with industry averages, hinting at a potential value edge. No dividend is paid, and the “Extreme Greed” reading on the Fear & Greed Index (94.6) suggests the market may be overly optimistic despite the weak earnings profile. Given the mix of technical weakness, sizable cash reserves, and a low‑cost valuation, the stock sits at a crossroads between short‑term pressure and a longer‑term turnaround opportunity.
On the fundamentals side, revenue has contracted 17.5% year‑over‑year to roughly $29.8 million, and margins are deep in the red (gross margin 48%, operating margin –17.8%). The company posted a trailing EPS of –$0.03 and a forward EPS of –$0.41, resulting in a negative forward P/E of –8.73, which renders traditional valuation ratios less informative. Nevertheless, the balance sheet is strong, with $46.5 million in cash and virtually no debt (debt‑to‑equity 0.5%). The price‑to‑book of 1.28 and price‑to‑sales of 2.10 are modest compared with industry averages, hinting at a potential value edge. No dividend is paid, and the “Extreme Greed” reading on the Fear & Greed Index (94.6) suggests the market may be overly optimistic despite the weak earnings profile. Given the mix of technical weakness, sizable cash reserves, and a low‑cost valuation, the stock sits at a crossroads between short‑term pressure and a longer‑term turnaround opportunity.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- price below key moving averages
- decreasing volume and high short‑term volatility
- negative earnings and revenue decline
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- strong cash position with minimal debt
- price-to-book and price-to-sales suggest modest undervaluation
- uncertain path to profitability
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- potential upside from platform scaling and AI tools
- low beta and sizable liquidity cushion
- valuation metrics imply upside if turnaround materializes
Key Metrics & Analysis
Financial Health
Revenue Growth-17.50%
Profit Margin-1.98%
P/E Ratio-8.7
ROE-1.23%
ROA-2.58%
Debt/Equity0.01
P/B Ratio1.3
Op. Cash Flow$-3565743
Free Cash Flow$-5409263
Industry P/E16.2
Technical Analysis
TrendBearish
RSI46.6
Support$3.34
Resistance$3.78
MA 20$3.59
MA 50$3.79
MA 200$4.15
MACDBullish
VolumeDecreasing
Fear & Greed Index94.59
Valuation
GradeUndervalued
TypeValue
Risk Assessment
Beta0.44
Volatility38.91%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.